These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 1319149)
1. Limited selectivity of a synthetic erbstatin derivative for tyrosine kinase and cell growth inhibition. Treuner M; Böhmer FD; Schulze W; Petuchov SP; Grosse R Biochem Int; 1992 Mar; 26(4):617-25. PubMed ID: 1319149 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell growth: effects of the tyrosine kinase inhibitor CGP 53716. Major TC; Keiser JA J Pharmacol Exp Ther; 1997 Oct; 283(1):402-10. PubMed ID: 9336349 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635 [TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. Panek RL; Lu GH; Klutchko SR; Batley BL; Dahring TK; Hamby JM; Hallak H; Doherty AM; Keiser JA J Pharmacol Exp Ther; 1997 Dec; 283(3):1433-44. PubMed ID: 9400019 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. Dahring TK; Lu GH; Hamby JM; Batley BL; Kraker AJ; Panek RL J Pharmacol Exp Ther; 1997 Jun; 281(3):1446-56. PubMed ID: 9190882 [TBL] [Abstract][Full Text] [Related]
6. In situ inhibition of tyrosine protein kinase by erbstatin. Imoto M; Umezawa K; Sawa T; Takeuchi T; Umezawa H Biochem Int; 1987 Nov; 15(5):989-95. PubMed ID: 3501720 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of basic fibroblast growth factor-mediated tyrosine phosphorylation and protein synthesis by PD 145709, a member of the 2-thioindole class of tyrosine kinase inhibitors. Fry DW; Nelson JM Anticancer Drug Des; 1995 Dec; 10(8):607-22. PubMed ID: 8595121 [TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners. Showalter HD; Sercel AD; Leja BM; Wolfangel CD; Ambroso LA; Elliott WL; Fry DW; Kraker AJ; Howard CT; Lu GH; Moore CW; Nelson JM; Roberts BJ; Vincent PW; Denny WA; Thompson AM J Med Chem; 1997 Feb; 40(4):413-26. PubMed ID: 9046331 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker BJ; Lydon NB Cancer Res; 1996 Jan; 56(1):100-4. PubMed ID: 8548747 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Reddy KB; Mangold GL; Tandon AK; Yoneda T; Mundy GR; Zilberstein A; Osborne CK Cancer Res; 1992 Jul; 52(13):3636-41. PubMed ID: 1617636 [TBL] [Abstract][Full Text] [Related]
13. Differential inhibitory effects of TGF-beta on EGF-, PDGF-, and HBGF-1-stimulated MG63 human osteosarcoma cell growth: possible involvement of growth factor interactions at the receptor and postreceptor levels. Mioh H; Chen JK J Cell Physiol; 1989 Jun; 139(3):509-16. PubMed ID: 2472412 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide. Shawver LK; Schwartz DP; Mann E; Chen H; Tsai J; Chu L; Taylorson L; Longhi M; Meredith S; Germain L; Jacobs JS; Tang C; Ullrich A; Berens ME; Hersh E; McMahon G; Hirth KP; Powell TJ Clin Cancer Res; 1997 Jul; 3(7):1167-77. PubMed ID: 9815796 [TBL] [Abstract][Full Text] [Related]
15. Use of selective tyrosine kinase blockers to monitor growth factor receptor dephosphorylation in intact cells. Böhmer FD; Böhmer A; Obermeier A; Ullrich A Anal Biochem; 1995 Jul; 228(2):267-73. PubMed ID: 8572305 [TBL] [Abstract][Full Text] [Related]
16. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41. Matheson SL; McNamee JP; Jean-Claude BJ Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201 [TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. Rewcastle GW; Palmer BD; Bridges AJ; Showalter HD; Sun L; Nelson J; McMichael A; Kraker AJ; Fry DW; Denny WA J Med Chem; 1996 Feb; 39(4):918-28. PubMed ID: 8632415 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Cunningham BD; Threadgill MD; Groundwater PW; Dale IL; Hickman JA Anticancer Drug Des; 1992 Oct; 7(5):365-84. PubMed ID: 1388629 [TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Taverna D; Groner B; Hynes NE Cell Growth Differ; 1991 Mar; 2(3):145-54. PubMed ID: 1676295 [TBL] [Abstract][Full Text] [Related]
20. The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition. Stanwell C; Burke TR; Yuspa SH Cancer Res; 1995 Nov; 55(21):4950-6. PubMed ID: 7585535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]